Supracor: a new multifocal ablation platform for management of presbyopia

Poster Details

First Author: T.Abdel Wahab EGYPT

Co Author(s):                  

Abstract Details

Purpose:

Is to evaluate efficacy, safety and predictability of Supracor as a central presbylasik, multifocal ablation algorithm. Evaluating pre and postoperative NUCVA, DUCVA and high order aberrations.

Setting:

Clear Vision Center

Methods:

A retrospective, non-comparative single center case series study. 20 eyes of 10 hyperopic presbyopia patients treated bilaterally with Supracor ( a multifocal, central presbylasik ) using Technolas 271P excimer laser and Moria M2 microkeratome . Mean age 50.2Y with pre operative SE +1.72 +0.34 D ,near addition +2.00 + 0.45D In all cases Orbscan , Z wavefronf aberrometry, manifest UCNVA & UCDVA was completed for 6 months follow-up period.

Results:

At 6 months 2 eyes lost 1line for BCDVA. UCNVA 95% see J3 or better SE of distance refraction shifts to myopia & improved in 3-6 months. Binocular UCDVA 100% 0.8 or better

Conclusions:

Supracor is a safe, effective and predictable binocular solution for hyperopic presbyopia . Supracor induces negative spherical aberrations, which increases depth of focus. FINANCIAL DISCLOSURE?: ... travel has been funded, fully or partially, by a competing company